Jazz Pharmaceuticals

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

Retrieved on: 
星期三, 四月 24, 2024
Lurbinectedin, BTC, ASCO, BLA, Abstract, Annual general meeting, Jazz Pharmaceuticals, Society, Research, Nightclub

DUBLIN, April 24, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago. Presentations include data from trials of zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.

Key Points: 
  • DUBLIN, April 24, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
  • A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.
  • "We are excited to present data across our oncology pipeline and portfolio at ASCO, particularly the opportunity to provide updated data from the pivotal Phase 2b HERIZON-BTC-01 trial of zanidatamab in HER2-positive BTC presented at last year's meeting.
  • A full list of Jazz or partner-supported presentations at the 2024 ASCO Annual Meeting follows:

DATAcc by DiMe Launches Core Measures for Sleep

Retrieved on: 
星期三, 四月 24, 2024
J&J, Defense Innovation Unit, Sage Bionetworks, Parkinson's disease, TC, Eli Lilly and Company, Boston University, Drug development, Veterans' affairs, Health, National Sleep Foundation, Partnership, Jazz Pharmaceuticals, Research, EHealth, Roche, Alzheimer's disease, Environment, Disease, Duke University, UCB, Medical device, Digital health, Government, GSK, MindMed, Mental health, Patient, TNO, Dime, PD, Dementia, Pharmaceutical industry

BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released a core set of digital measures and resources for sleep. Together, these will increase the availability of high-quality, standardized, and transparent sleep assessments in a natural environment and transform research and care to advance overall population health. The core digital measures set and resources were developed by a cross-disciplinary group of experts designed to maintain broad applicability across research, care, and multiple disease areas.

Key Points: 
  • BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released a core set of digital measures and resources for sleep .
  • Better sleep means better health, and disrupted sleep can indicate or cause chronic conditions ranging from primary sleep disorders to mental health conditions to Parkinson's Disease to Women's health to cardiac conditions and more.
  • "The core digital measures of sleep and accompanying resources now make it more accessible than ever before to incorporate sleep data into trials and care plans where sleep was previously inaccessible.
  • In addition to the core measures and over 15 new resources, the project team also added sleep digital measurement products to the Library of Digital Measurement Products.

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Retrieved on: 
星期三, 四月 17, 2024
IST, Jazz Pharmaceuticals, Interest

DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.

Key Points: 
  • DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.
  • ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
  • Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Retrieved on: 
星期三, 四月 17, 2024
IST, Jazz Pharmaceuticals, Interest

DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.

Key Points: 
  • DUBLIN, April 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 first quarter financial results on Wednesday, May 1, 2024, after the close of the U.S. financial markets.
  • ET / 9:30 p.m. IST to discuss 2024 first quarter financial results and provide a business and financial update.
  • Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Retrieved on: 
星期二, 四月 9, 2024
Survival, Immunotherapy, Neuroblastoma, Patient, Journal, EFS, Acquisition, Jazz Pharmaceuticals, Cancer, Radiation, Haematopoietic system, Pharmaceutical industry

This will be Essential’s first clinical development-stage asset and is targeted at addressing significant unmet needs in paediatric oncology patients.

Key Points: 
  • This will be Essential’s first clinical development-stage asset and is targeted at addressing significant unmet needs in paediatric oncology patients.
  • Simon Ball, CEO and co-founder of Renaissance Pharma, who has significant scientific and commercial expertise within the space, will continue to work with Essential Pharma on Hu14.18’s development, as will many of the Renaissance Pharma team.
  • Approximately half of all neuroblastoma patients have high risk (HRNB) disease which has an overall survival of ~50% over five years23.
  • Essential Pharma will be responsible for clinical development and defining the optimal route for regulatory approval and eventual commercial launch of Hu14.18.

Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer

Retrieved on: 
星期四, 三月 28, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sleep, Monitor Deloitte, Growth, Patient, Acquisition, Cancer, Spacecraft, Senior, Therapy, Bain, Partner, GW Pharmaceuticals, ADC, Bain & Company, Corporate development, Jazz Pharmaceuticals, Pharmaceutical industry

Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).

Key Points: 
  • Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the company as President and Chief Executive Officer (CEO).
  • “I am delighted to welcome George to the Mythic team,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at Mythic Therapeutics.
  • Prior to that, Dr. Eliades spent over 20 years at Bain & Company and Monitor Group, advising biotech clients in corporate strategy, M&A, growth and digital-driven transformations.
  • Dr. Eliades stated, “I’m incredibly excited to join Mythic and work toward improving outcomes for more cancer patients through our pipeline of innovative ADCs.

SAPA-GP Hosted the 2024 Annual Conference Highlighting the Innovating Biopharma Frontier

Retrieved on: 
星期二, 三月 12, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Health informatics, Informatics, COVID 19, McKinsey & Company, COVID, Conference, Data science, Spark Therapeutics, AI, Volunteering, Section, MBA, Yale School of Medicine, Therapy, Process, Drug development, Yale school, Multimedia, Proposition, Jazz Pharmaceuticals

On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.

Key Points: 
  • On March 9, 2024, SAPA-GP ( https://sapagp.org/ ) hosted its 22nd Annual Conference at the Sheraton Valley Forge Hotel, northwest of Philadelphia.
  • Fangning Zhang, MBA, Partner at McKinsey & Company, delivered the conference opening keynote speech “Path towards Value Creation – China Biopharma Innovation Trends”.
  • “Our conference has been very successful in capturing the latest trends foretelling the direction of biopharma industry.
  • The 2024 SAPA-GP Annual Conference was a great gathering of life scientists, pharmaceutical experts, and business leaders from diverse backgrounds, experiences, and accomplishments.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
星期四, 三月 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

TSC Alliance® to Host 23rd Annual Comedy for a Cure® on April 14 in Los Angeles

Retrieved on: 
星期五, 三月 15, 2024
TSC, Jim, Learning, Parks and Recreation, Disease, Patient, The King of Queens, Neoplasm, DSM-IV codes, Research, Courage, Vibiana, The Tonight Show, Ovation, Movement disorder, Jazz, Jazz Pharmaceuticals, Comedy, Cure, Pharmaceutical industry

LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.

Key Points: 
  • LOS ANGELES, March 15, 2024 /PRNewswire/ -- Today, the TSC Alliance ® announced its 23nd Annual Comedy for a Cure ® will be held Sunday, April 14, at the historic Vibiana in Los Angeles.
  • "Every year, Comedy for Cure helps our organization raise significant funds to further TSC research, offer expanded support programs and increase awareness about the disease," said Kari Luther Rosbeck, TSC Alliance President & CEO.
  • "Over the years, this signature event has raised almost $6 million cumulatively to help improve the lives of everyone affected by TSC."
  • Comedy for a Cure also offers the opportunity to pay tribute to those who have made significant impacts in the right against TSC.

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

Retrieved on: 
星期二, 三月 12, 2024
GEA, Patient, Breast cancer, Interest, Jazz Pharmaceuticals, Cancer, BTC, Cholangiocarcinoma

DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.

Key Points: 
  • DUBLIN, March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19, from 8:00 a.m. to 10:00 a.m.
  • ET, focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers.
  • Interested parties may register for the zanidatamab R&D Day webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.